Literature DB >> 8906030

Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits.

T W Wilson1, H S Chan, G M Moselhy, D D Heydt, C M Frey, B L Gallie.   

Abstract

OBJECTIVE: To investigate whether cryotherapy, which induces a serous effusion in retina, might increase access of systemic chemotherapy into the vitreous.
METHODS: The right eyes of 18 rabbits were treated with triple or single freeze-thaw cryotherapy at 1 or 2 locations, 1 day before administering intravenous carboplatin with or without cyclosporine. Control left eyes received no cryotherapy. The rabbits were killed 2 or 24 hours after chemotherapy, and carboplatin concentrations were measured in the vitreous of each eye and in blood.
RESULTS: A significant increase was found in intravitreal carboplatin concentrations when cryotherapy was applied (P < .001) or high-dose cyclosporine was administered (P < .001) and if 2 locations were frozen compared with 1 location frozen (P = .02). Intravitreal carboplatin concentrations were always significantly greater after cryotherapy, either when the corresponding blood carboplatin concentrations were high (2 hours after completing treatment) or when they had dropped to much lower levels (at 24 hours). The triple freeze-thaw technique did not yield significantly better results than a single freeze-thaw technique.
CONCLUSION: Cryotherapy administered 24 hours before chemotherapy significantly increased the intravitreal penetration of carboplatin, and this strategy may enhance the capacity of chemotherapy to cure intraocular retinoblastoma, particularly avascular tumors such as vitreous seeds.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906030     DOI: 10.1001/archopht.1996.01100140590011

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  10 in total

1.  Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group.

Authors:  Debra L Friedman; Mark Krailo; Doojduen Villaluna; Dan Gombos; Bryan Langholz; Rima Jubran; Carol Shields; Linn Murphree; Joan O'Brien; Sandra Kessel; Carlos Rodriguez-Galindo; Murali Chintagumpala; Anna T Meadows
Journal:  Pediatr Blood Cancer       Date:  2016-12-26       Impact factor: 3.167

2.  Intravitreal injection of melphalan for intraocular retinoblastoma.

Authors:  Shigenobu Suzuki; Yukiko Aihara; Miyuki Fujiwara; Shuichi Sano; Akihiro Kaneko
Journal:  Jpn J Ophthalmol       Date:  2015-03-26       Impact factor: 2.447

3.  The Role of Cryotherapy in Vitreous Concentrations of Topotecan Delivered by Episcleral Hydrogel Implant.

Authors:  Martina Kodetova; Radka Hobzova; Jakub Sirc; Jiri Uhlik; Katerina Dunovska; Karel Svojgr; Ana-Irina Cocarta; Andrea Felsoova; Ondrej Slanar; Martin Sima; Igor Kozak; Pavel Pochop
Journal:  Pharmaceutics       Date:  2022-04-20       Impact factor: 6.525

Review 4.  The role of intravitreal chemotherapy for retinoblastoma.

Authors:  Fairooz P Manjandavida; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

Review 5.  Retinoblastoma: achieving new standards with methods of chemotherapy.

Authors:  Swathi Kaliki; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

6.  First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment.

Authors:  Francis L Munier; Pascal Mosimann; Francesco Puccinelli; Marie-Claire Gaillard; Christina Stathopoulos; Susan Houghton; Ciara Bergin; Maja Beck-Popovic
Journal:  Br J Ophthalmol       Date:  2016-12-07       Impact factor: 4.638

7.  Intra-arterial Chemotherapy as Primary Treatment for Cavitary Retinoblastoma: Excellent Response in Eight Tumors.

Authors:  Yuxi Zheng; Michael T Froehler; Debra L Friedman; Anthony B Daniels
Journal:  Ophthalmol Retina       Date:  2020-08-24

8.  Retinoblastoma: a three-year-study at a Brazilian medical school hospital.

Authors:  Maria Teresa Brizzi Chizzotti Bonanomi; Maria Tereza Assis de Almeida; Lilian Maria Cristofani; Vicente Odone Filho
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

9.  Commentary: Periocular topotecan for retinoblastoma.

Authors:  Minal Sharma; Vikas Khetan
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

Review 10.  Modern treatment of retinoblastoma: A 2020 review.

Authors:  David Ancona-Lezama; Lauren A Dalvin; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.